US regulators reject GSK’s Nucala for COPD
GlaxoSmithKline’s bid to expand the use of its biologic Nucala in the US to include patients with coronary pulmonary obstructive disorder (COPD) has hit a significant setback.
Read More
Tag: METREX
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
